BRIEF-Cytokinetics Announces Nmpa Approval Of Myqorzo® In China

Reuters12-17 20:47

BRIEF-<a href="https://laohu8.com/S/CYTK">Cytokinetics</a> Announces Nmpa Approval Of Myqorzo® In China

Dec 17 (Reuters) - Cytokinetics Inc CYTK.O:

CYTOKINETICS ANNOUNCES NMPA APPROVAL OF MYQORZO® (AFICAMTEN) IN CHINA FOR PATIENTS WITH OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY
CYTOKINETICS INC - APPROVAL TRIGGERS $7.5 MILLION MILESTONE PAYMENT FROM SANOFI
CYTOKINETICS INC - ELIGIBLE FOR UP TO $142.5 MILLION IN MILESTONE PAYMENTS
CYTOKINETICS INC - FDA REVIEWING NDA FOR AFICAMTEN WITH PDUFA DATE DECEMBER 26, 2025

Source text: ID:nGNX8mZ7C9

Further company coverage: CYTK.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2592997789?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-17 20:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2592997789","market":"nz","top_or_hot":-1,"title":"BRIEF-Cytokinetics Announces Nmpa Approval Of Myqorzo® In China","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/CYTK\">Cytokinetics</a> Announces Nmpa Approval Of Myqorzo® In China </title></head><body><p><span>Dec 17 (Reuters)</span><span> - </span>Cytokinetics Inc <span>CYTK.O</span>:</p><ul><li><p>CYTOKINETICS ANNOUNCES NMPA APPROVAL OF MYQORZO® (AFICAMTEN) IN CHINA  FOR PATIENTS WITH OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY</p></li><li><p>CYTOKINETICS INC - APPROVAL TRIGGERS $7.5 MILLION MILESTONE PAYMENT FROM SANOFI</p></li><li><p>CYTOKINETICS INC - ELIGIBLE FOR UP TO $142.5 MILLION IN MILESTONE PAYMENTS</p></li><li><p>CYTOKINETICS INC - FDA REVIEWING NDA FOR AFICAMTEN WITH PDUFA DATE DECEMBER 26, 2025</p></li></ul><p>Source text: <span>ID:nGNX8mZ7C9</span></p><p>Further company coverage: <span>CYTK.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Cytokinetics Announces Nmpa Approval Of Myqorzo® In China</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Cytokinetics Announces Nmpa Approval Of Myqorzo® In China\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-17 20:47</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/CYTK\">Cytokinetics</a> Announces Nmpa Approval Of Myqorzo® In China </title></head><body><p><span>Dec 17 (Reuters)</span><span> - </span>Cytokinetics Inc <span>CYTK.O</span>:</p><ul><li><p>CYTOKINETICS ANNOUNCES NMPA APPROVAL OF MYQORZO® (AFICAMTEN) IN CHINA  FOR PATIENTS WITH OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY</p></li><li><p>CYTOKINETICS INC - APPROVAL TRIGGERS $7.5 MILLION MILESTONE PAYMENT FROM SANOFI</p></li><li><p>CYTOKINETICS INC - ELIGIBLE FOR UP TO $142.5 MILLION IN MILESTONE PAYMENTS</p></li><li><p>CYTOKINETICS INC - FDA REVIEWING NDA FOR AFICAMTEN WITH PDUFA DATE DECEMBER 26, 2025</p></li></ul><p>Source text: <span>ID:nGNX8mZ7C9</span></p><p>Further company coverage: <span>CYTK.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CYTK","symbol_name":"Cytokinetics","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nTUAW2PGJ:1","article_id":"2592997789","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2592997789","pubTimestamp":1765975620,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Cytokinetics Announces Nmpa Approval Of Myqorzo In China Dec 17 (Reuters) - Cytokinetics Inc CYTK.O:CYTOKINETICS ANNOUNCES NMPA APPROVAL OF MYQORZO (AFICAMTEN) IN CHINA  FOR PATIENTS WITH OBSTRU","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CYTK":"Cytokinetics","BK4588":"碎股","BK4585":"ETF&股票定投概念","BK4505":"高瓴资本持仓","BK4139":"生物科技"},"translate_title":"BRIEF-Cytokinetics宣布Myqorzo获得Nmpa批准®在中国","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CYTK":0.9},"content_text":"BRIEF-Cytokinetics Announces Nmpa Approval Of Myqorzo® In China Dec 17 (Reuters) - Cytokinetics Inc CYTK.O:CYTOKINETICS ANNOUNCES NMPA APPROVAL OF MYQORZO® (AFICAMTEN) IN CHINA  FOR PATIENTS WITH OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHYCYTOKINETICS INC - APPROVAL TRIGGERS $7.5 MILLION MILESTONE PAYMENT FROM SANOFICYTOKINETICS INC - ELIGIBLE FOR UP TO $142.5 MILLION IN MILESTONE PAYMENTSCYTOKINETICS INC - FDA REVIEWING NDA FOR AFICAMTEN WITH PDUFA DATE DECEMBER 26, 2025Source text: ID:nGNX8mZ7C9Further company coverage: CYTK.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2592997789","isCrawlerRequest":true}